To study the sensitivity to the targeted therapies ibrutinib, idelalisib and venetoclax in CLL cells collected at time T0 (after progression on ibrutinib, Fig. 3a), the cells were treated with each drug at clinically relevant drug concentrations (1–10,000 nM) for 30 min, followed by 5 min anti-IgM stimulation. Here, CD40LG is linked to B-cell chronic lymphocytic leukemia.